INVO Fertility, Inc. (Nasdaq: IVF) (“INVO Fertility” or the “Company”), a healthcare services fertility company focused on expanding access to advanced treatment through the establishment, acquisition and operation of fertility clinics, today announced fourth quarter and full year 2024 financial results.
Q4 2024 Financial Highlights (all metrics compared to Q4 2023 unless otherwise noted)
- Revenue was $1,685,966, an increase of 22% compared to $1,381,754.
- Consolidated clinic revenue from the Company's INVO Center in Atlanta, Georgia, and fertility clinic in Madison, Wisconsin increased 24% to $1,687,300, compared to $1,362,938.
- Revenue from all clinics, including both consolidated and equity method clinics, was $2,034,332, an increase of 24% compared to $1,634,912.
- Net loss increased to $(3.6) million compared to $(2.0) million as a result of the addition of NAYA Therapeutics during the period and the corresponding merger costs.
- Adjusted EBITDA (see table included) was $(450,908) compared to $(1.0) million in the prior year. Adjusted EBITDA does not include the loss from NAYA Therapeutics, Inc. (“NAYA TX”) or corresponding merger related costs, which, as recently announced, the Company is in the process of divesting a majority stake in.
2024 Financial Highlights (all metrics compared to 2023 unless otherwise noted)
- Revenue was $6,532,000, an increase of 116% compared to $3,020,575.
- Consolidated clinic revenue increased 125% to $6,450,431, compared to $2,862,574.
- Revenue from all clinics was $7,731,177, including both consolidated and equity method clinics, an increase of 78% compared to $4,346,933.
- Net loss increased to $(9.1) million compared to $(8.0) million as a result of the addition of NAYA Therapeutics and corresponding merger costs.
- Adjusted EBITDA (see table included) was $(2.2) compared to $(4.9) million.
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.